In medical news:

The FDA approved a new monthly formulation of buprenorphine – a medication assisted treatment (MAT) option – for the treatment of opioid use disorder. In a statement about the approval, FDA Commissioner Scott Gottlieb endorsed the use of MAT, explaining: “Medication-assisted treatment for opioid addiction uses drugs to stabilize brain chemistry, reduce or block the euphoric effects of opioids, relieve physiological cravings and normalize body functions. [MAT] treatments have been demonstrated to be safe and effective in combination with counseling and psychosocial support.”

Read more here.

Leave a Comment

Your email address will not be published. Required fields are marked *